<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219579</url>
  </required_header>
  <id_info>
    <org_study_id>HGRyu_AT-III</org_study_id>
    <nct_id>NCT04219579</nct_id>
  </id_info>
  <brief_title>Antithrombin III Concentrate After Liver Transplantation</brief_title>
  <official_title>Continuous Versus Intermittent Infusion of Human Antithrombin III Concentrate in the Immediate Postoperative Period After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to demonstrate more effective administration method of AT-III in
      immediate post-liver transplantation period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antithrombin III(AT-III) concentrates have been used to prevent critical thrombosis in the
      immediate post-liver transplantation period without clear evidence regarding the optimal dose
      or administration scheme.

      The investigators retrospectively analyzed the clinical data from the patients who received
      liver transplantation and developed pharmacokinetic model of AT-III in the previous research.
      According to this study, optimal AT-III activity level will be well-maintained with smaller
      dose with continuous infusion than with intermittent infusion which is widely accepted way of
      administration currently.

      A prospective study was planned to show the more effective manner of AT-III concentrate
      administration after liver transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients within target range at postoperative 72 hours</measure>
    <time_frame>72 hours after liver transplantation</time_frame>
    <description>Proportion of patients whose AT-III activity level is within the target range (80-120%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients within target range at postoperative 12/24/48/84 hours</measure>
    <time_frame>12/24/48/84 hours after liver transplantation</time_frame>
    <description>Proportion of patients whose AT-III activity level is within the target range (80-120%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AT-III level values within target range</measure>
    <time_frame>12/24/48/72/84 hours after liver transplantation</time_frame>
    <description>Among the measured AT-III activity levels, proportion of the values within the target range (80-120%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required for AT-III level value to fall within target range</measure>
    <time_frame>operation day ~ postoperative day 7</time_frame>
    <description>Time required for AT-III level value to fall within target range (80-120%, hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration for cessation of AT-III concentrate administration</measure>
    <time_frame>operation day ~ postoperative day 7</time_frame>
    <description>AT-III infusion is stopped for 24 hours when AT-III plasma activity level exceeds 120%, then restarted after the value is confirmed to be less than 120%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding requiring intervention</measure>
    <time_frame>operation day ~ postoperative day 7</time_frame>
    <description>Bleeding requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis event</measure>
    <time_frame>operation day ~ postoperative day 7</time_frame>
    <description>Hepatic artery thrombosis, portal vein thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>through the hospital day, an average of 14 days</time_frame>
    <description>number of days from operation to discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately after operation, 2000 international unit (IU) of Antithrombin-III (AT-III) concentrate is loaded for 1 hour. AT-III concentrate 3000 IU is continuously infused through following 71 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every 6 hours, 500 IU of AT-III concentrate is infused through 1 hour during the first 72 hours after liver transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III, continuous infusion</intervention_name>
    <description>Antithrombin-III is administered continuously</description>
    <arm_group_label>Continuous infusion</arm_group_label>
    <other_name>Antithrombin III, human</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III, Intermittent infusion</intervention_name>
    <description>Antithrombin-III is administered intermittently</description>
    <arm_group_label>Intermittent infusion</arm_group_label>
    <other_name>Antithrombin III, human</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled operation

          -  Living donor liver transplantation

          -  Adult patients (&gt;=18 years old)

        Exclusion Criteria:

          -  Patients under 18 years old

          -  Emergency operation

          -  Deceased donor liver transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Geol Ryu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Rim KIM, MD</last_name>
    <phone>82-2-2072-7361</phone>
    <email>petitbelle22@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ho Geol Ryu, MD, PhD</last_name>
    <phone>82-2-2072-2065</phone>
    <email>hogeol@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Geol Ryu, MD, PhD</last_name>
      <phone>+82-2072-2065</phone>
      <email>hogeol@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Seung-Young Oh, MD, MS</last_name>
      <phone>+82-2072-3098</phone>
      <email>faun1226@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ho Geol Ryu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ho Geol Ryu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>antithrombin III</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>administration method</keyword>
  <keyword>dosage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

